Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. (2017)
Attributed to:
IDENTIFICATION OF NUCLEAR PATHWAYS THAT ARE CAUSALLY INVOLVED IN NUCLEOLAR TARGETING OF NF-KAPPAB/RELA.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41598-017-12222-9
PubMed Identifier: 28931905
Publication URI: http://europepmc.org/abstract/MED/28931905
Type: Journal Article/Review
Volume: 7
Parent Publication: Scientific reports
Issue: 1
ISSN: 2045-2322